February 25, 2026 — Novo Nordisk’s anticipated weight-loss drug, CagriSema, has been deemed ineffective compared to existing treatments, leading to a significant drop in the company’s stock value. The news comes after trial results showed CagriSema’s performance lagging behind Eli Lilly’s competing drug, causing Novo’s shares to plummet over 16%.
The announcement from Denmark on Monday revealed that participants on a standard dose of CagriSema lost 20.2% of their weight over 84 weeks. In contrast, Eli Lilly’s tirzepatide achieved a 23.6% weight loss, positioning it as the superior treatment in the ongoing battle of obesity drugs.
Novo Nordisk’s Market Struggles
Novo Nordisk, once the leader in the anti-obesity GLP-1 market, now faces fierce competition. The company’s market valuation has dropped dramatically, losing 60% over the past year and erasing $475 billion in shareholder wealth since its peak in 2024.
Michael Shah, a Bloomberg Intelligence analyst, described the trial as a misstep. “The trial has backfired,” he said, highlighting that the results were unexpected and extended Lilly’s advantage. Meanwhile, Chris O’Donnell, founder of My Weight Loss Clinic, emphasized the need for diverse treatment options, noting that not every drug suits every patient.
Expert Opinions and Industry Reactions
Dr. Kieran Dang, chief medical officer at Mosh, downplayed the trial’s weight-loss figures, stating, “Both are large amounts of weight that is more than what many people using medical weight loss products are aiming for.” He stressed the importance of combining medication with structured weight loss programs for better outcomes.
Novo Nordisk’s chief scientific officer, Martin Holst Lange, indicated that further studies are necessary to fully assess CagriSema’s potential. Despite the setback, Novo remains committed to launching CagriSema by 2027, banking on its strong weight-loss profile and cardiometabolic benefits.
Legal Battles and Competitive Pressures
The competitive landscape is further complicated by legal challenges. Novo recently sued Hims & Hers for allegedly infringing on its intellectual property with a “knock-off” version of Wegovy. The lawsuit led to Hims & Hers pulling the product, impacting its share value significantly.
Adding to the intrigue, Hims & Hers acquired Australian weight loss start-up Eucalyptus for $1.6 billion, reflecting a strategic expansion into new markets. However, the acquisition comes amid a volatile period for the company, as its shares have halved in value over the past year.
Future Prospects and Industry Implications
Novo Nordisk’s challenges underscore the intense competition in the pharmaceutical industry, particularly in the lucrative obesity treatment market. The company’s CEO, Maziar Mike Doustdar, remains optimistic, citing CagriSema’s superior results in large-scale trials used for regulatory approvals.
As Novo continues to navigate these challenges, the company is focused on innovation and strategic growth. The introduction of its consumer anti-obesity drug Wegovy in pill form in the US represents a potential avenue for recovery.
The unfolding scenario in the obesity drug market highlights the dynamic nature of pharmaceutical innovation and competition. As companies vie for dominance, the ultimate beneficiaries could be patients, who gain access to a broader range of treatment options.
With ongoing trials and strategic initiatives, Novo Nordisk aims to reclaim its position in the market. The company’s future moves will be closely watched by investors and industry analysts alike as it seeks to overcome current setbacks and capitalize on emerging opportunities.
